MX347805B - Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. - Google Patents

Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.

Info

Publication number
MX347805B
MX347805B MX2013004753A MX2013004753A MX347805B MX 347805 B MX347805 B MX 347805B MX 2013004753 A MX2013004753 A MX 2013004753A MX 2013004753 A MX2013004753 A MX 2013004753A MX 347805 B MX347805 B MX 347805B
Authority
MX
Mexico
Prior art keywords
immunodiagnostics
fviii
immune tolerance
tolerance induction
peptides
Prior art date
Application number
MX2013004753A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004753A (es
Inventor
Schwarz Hans-Peter
Nora Steinitz Katharina
Maria Wilhelmina Van Helden Paula
Maria Reipert Birgit
Ehrlich Hartmut
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2013004753A publication Critical patent/MX2013004753A/es
Publication of MX347805B publication Critical patent/MX347805B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
MX2013004753A 2010-10-27 2011-10-27 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. MX347805B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29
PCT/US2011/058165 WO2012058480A1 (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Publications (2)

Publication Number Publication Date
MX2013004753A MX2013004753A (es) 2013-09-13
MX347805B true MX347805B (es) 2017-05-15

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004753A MX347805B (es) 2010-10-27 2011-10-27 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.

Country Status (20)

Country Link
US (3) US8969524B2 (enExample)
EP (2) EP2632479B1 (enExample)
JP (2) JP6122780B2 (enExample)
KR (2) KR102222864B1 (enExample)
CN (2) CN104926947A (enExample)
AR (1) AR083586A1 (enExample)
AU (2) AU2011319747C1 (enExample)
BR (1) BR112013010362A2 (enExample)
CA (1) CA2815239C (enExample)
DK (1) DK2632479T3 (enExample)
EA (1) EA034494B1 (enExample)
ES (2) ES2639039T3 (enExample)
HK (1) HK1215442A1 (enExample)
MX (1) MX347805B (enExample)
NZ (2) NZ609474A (enExample)
PL (2) PL3260132T3 (enExample)
PT (1) PT2632479T (enExample)
SG (2) SG10201600656WA (enExample)
TW (3) TWI580430B (enExample)
WO (1) WO2012058480A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
JP6488376B2 (ja) * 2014-06-12 2019-03-20 ユニヴァーシティ オブ ハワイUniversity Of Hawaii 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1766412B1 (en) * 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations

Also Published As

Publication number Publication date
EA034494B1 (ru) 2020-02-13
PL3260132T3 (pl) 2022-08-08
US20150203567A1 (en) 2015-07-23
TW201708251A (zh) 2017-03-01
PL2632479T3 (pl) 2017-09-29
AU2011319747C1 (en) 2016-07-14
US9512198B2 (en) 2016-12-06
AU2011319747B2 (en) 2016-01-07
EP3260132B1 (en) 2022-02-09
KR102222864B1 (ko) 2021-03-04
US20120135019A1 (en) 2012-05-31
US8969524B2 (en) 2015-03-03
CA2815239C (en) 2019-02-26
EP2632479B1 (en) 2017-06-14
JP2017095463A (ja) 2017-06-01
WO2012058480A1 (en) 2012-05-03
BR112013010362A2 (pt) 2016-08-02
TW201730205A (zh) 2017-09-01
ES2912455T3 (es) 2022-05-26
AR083586A1 (es) 2013-03-06
CN103298482A (zh) 2013-09-11
NZ609474A (en) 2015-06-26
CA2815239A1 (en) 2012-05-03
SG10201600656WA (en) 2016-02-26
AU2016202155B2 (en) 2018-02-01
JP6122780B2 (ja) 2017-04-26
HK1215442A1 (zh) 2016-08-26
JP2014505014A (ja) 2014-02-27
PT2632479T (pt) 2017-07-24
ES2639039T3 (es) 2017-10-25
MX2013004753A (es) 2013-09-13
KR102040867B1 (ko) 2019-11-07
CN103298482B (zh) 2015-08-19
KR20190126189A (ko) 2019-11-08
US20170267743A1 (en) 2017-09-21
AU2016202155A1 (en) 2016-04-28
TWI580430B (zh) 2017-05-01
EA201390617A1 (ru) 2013-10-30
KR20130128404A (ko) 2013-11-26
TW201231065A (en) 2012-08-01
NZ703514A (en) 2017-02-24
AU2011319747A1 (en) 2013-05-02
EP3260132A1 (en) 2017-12-27
EP2632479A1 (en) 2013-09-04
DK2632479T3 (en) 2017-08-07
CN104926947A (zh) 2015-09-23
SG189914A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
EA201390617A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
NZ627078A (en) Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
IN2012DN06309A (enExample)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015006491A (es) Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2889371A4 (en) BACTEROIDES CECT 7771 AND USE THEREOF IN THE PREVENTION AND TREATMENT OF OVERWEIGHT, FAT SUPPORT AND METABOLIC AND IMMUNOLOGICAL CHANGES
IN2014KN02830A (enExample)
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
GB201118201D0 (en) Novel peptides
NZ701408A (en) Proteins that bind pi16 and uses thereof
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
CY1123049T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
PT2917232T (pt) Péptidos derivados do fator viii para uso no tratamento da hemofilia a
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX2015003225A (es) Antagonistas peptidicos del receptor de vasoresina 2.
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
EA201992559A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
GB201102090D0 (en) Antigenic polypeptide
AU345482S (en) Alu' sling cover dining chair
UA56500U (en) Myotonometer
AU345284S (en) Tailored couch
AU345486S (en) Alu' sling armchair
UA72827U (ru) Способ лечения гипертонической болезни у лиц пожилого возраста

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration